GWOXI Business Summary

Gwo Xi Stem Cell Applied Technology Co., Ltd. (6704.TWO) is a Taiwan-based biopharmaceutical leader specializing in the research, development, and commercialization of regenerative medicine and mesenchymal stem cell (MSC) therapies. The company operates a diversified revenue model encompassing the sale of stem cell-derived products (such as exosomes), technical application services including CDMO/CMO manufacturing, and specialized testing through its ISO-certified laboratories. Its primary business segments are divided into clinical-stage drug development—featuring a pipeline of candidates like GXHPC1 for liver cirrhosis and GXNPC1 for chronic stroke—and technical services such as stem cell banking and quality control testing. Gwo Xi differentiates itself through its proprietary Nigiro-Med® activation technology and its PIC/S GMP-compliant facility in the Hsinchu Biomedical Science Park. Within the regional biotech landscape, it competes directly with firms such as Allied Biotech (1780.TW), Pet Pharm Biotech (7762.TWO), BIONET Therapeutics (7808.TWO), and Synbio Tech (1295.TWO), maintaining a competitive edge as one of the first domestic entities to advance multiple stem cell therapies into Phase II and Phase III clinical trials. The company was founded in 2004 and is currently led by Chairman Dr. Ming-Hsi Chuang, a prominent figure in Taiwan’s regenerative medicine sector who has spearheaded the firm’s strategic shift toward international drug licensing and clinical expansion. The executive team includes CEO Chuan-Feng Chiu, who oversees market dynamics and strategic positioning, and CTO Po-Cheng Lin (also serving as VP of R&D), who is credited with mastering the company’s pharmaceutical-grade production processes and securing over 120 patents. The leadership team is supported by a board that includes representatives from notable institutional investors such as Kangshi Investment Co., Ltd. As of early 2026, the management has focused on a dual-track growth strategy, prioritizing domestic regulatory approvals under Taiwan’s Regenerative Medicine Act while aggressively pursuing out-licensing opportunities in Japan and Vietnam to integrate into the global regenerative medicine supply chain.